Drug delivery device innovation currently offers a clear opportunity for leaders to move from isolated innovation to integrated therapies, connected support and partnerships that improve the entire patient experience. CC invited 25 senior industry stakeholders to a Boston summit to explore and accelerate this shift. You can download your copy of our summit report below.
In a world where the blockbuster drug is king, investment in drug delivery device innovation can seem like an unnecessary risk. The prevailing assumption is that the drug generates the value, while the device’s role is simply to deliver it safely. We decided to bring the industry together to confront this thinking and to move the needle on innovation in this critical area.
This report reflects an essential truth. The future of drug delivery device innovation will be defined by a fundamental shift – with the greatest commercial opportunity lying not in designing a better device but designing better therapies with the device a critical element.
専門家
フィリップ・キャナー
With over twenty years' experience in medical device leadership, engineering, and management consultancy, Philip has led the development of an extensive range of medical technologies, with a particular focus on drug delivery.
チャーリー・ディーン
チャーリーはメディカルテクノロジー事業本部のサステナブルメディカルテクノロジーグループのリーダーであり、医療機器開発における機械設計と解析手法に精通しています。LCA（ライフサイクルアセスメント）の専門家として、医療製品の評価と設計を主導し、環境負荷の低減やサーキュラーエコノミーの推進に取り組んでいます。
Adam Tozer
Adam has over 10 years of experience helping organisations understand how emerging technologies can address unmet clinical needs and create differentiated healthcare solutions.
